Li Kang Biomedical Co Ltd (6242) — Cash Flow Quality Index
Li Kang Biomedical Co Ltd (6242) has a Cash Flow Quality Index of 2.42x as of December 2025. Operating cash flow of NT$67.23 Million exceeds net income of NT$27.82 Million, indicating high earnings quality where cash backs reported profits. Also explore balance sheet size of Li Kang Biomedical Co Ltd for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Li Kang Biomedical Co Ltd Cash Flow Quality Index (2002–2025)
Historical Cash Flow Quality Index for Li Kang Biomedical Co Ltd across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 6242 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Li Kang Biomedical Co Ltd (2002–2025)
Year-by-year earnings quality comparison for Li Kang Biomedical Co Ltd. For live market cap and the full company financial profile, see 6242 market cap overview.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.10x | NT$92.15 Million | NT$83.82 Million | ▲ +29.5% |
| 2024 | 0.85x | NT$65.38 Million | NT$77.02 Million | ▲ +22.1% |
| 2023 | 0.70x | NT$96.74 Million | NT$139.14 Million | ▼ -37.7% |
| 2022 | 1.12x | NT$157.24 Million | NT$140.80 Million | ▲ +17.3% |
| 2021 | 0.95x | NT$60.45 Million | NT$63.48 Million | ▲ +1.4% |
| 2020 | 0.94x | NT$81.67 Million | NT$86.94 Million | ▼ -26.9% |
| 2019 | 1.29x | NT$92.56 Million | NT$72.02 Million | ▼ -6.5% |
| 2018 | 1.38x | NT$105.53 Million | NT$76.74 Million | ▲ +66.3% |
| 2017 | 0.83x | NT$110.61 Million | NT$133.74 Million | ▼ -54.1% |
| 2016 | 1.80x | NT$110.82 Million | NT$61.51 Million | ▲ +49.0% |
| 2015 | 1.21x | NT$63.91 Million | NT$52.85 Million | ▼ -48.7% |
| 2002 | 2.36x | NT$45.87 Million | NT$19.46 Million | — |